Akeega Approved for BRCA2-Mutated Prostate Cancer

By News Health
2 months Ago

(MedPage Today) — The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on Friday.
The once-daily, fixed…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/119017

Author :

Publish date : 2025-12-15 19:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Reassuring Data on Autism and Prenatal COVID Vaccination

Advanced Therapies Show Similar Safety in Crohn’s Disease

New Autoimmune Disease CAR T Results ‘a Tremendous Success’

Super-Resolution Ultrasound Can Track Early Kidney Disease

Why self-expansion is the key to long-lasting love and friendship

Study: CTCL Increasing Among US Children, Young Adults